Download PDF
Kardiologie up2date 2014; 10(02): 121-134
DOI: 10.1055/s-0034-1377416
Herzrhythmusstörungen
© Georg Thieme Verlag KG Stuttgart · New York

Optimierte ICD-Therapie: Wie können inadäquate ICD-Schocks vermieden werden?

Carsten W. Israel
Further Information

Publication History

Publication Date:
28 July 2014 (online)

Also available at
    Permissions and Reprints All articles of this category

Abstract

ICD shocks can save lives but are associated with a reduced quality of life and may herald a deterioration of the underlying heart disease. Optimization of ICD programming can prevent inappropriate and unnecessary shocks which may be associated with an improved survival, as recent studies showed. This review provides recommendations on the use of enhanced detection criteria, antitachycardia pacing, tachycardia detection rates, and delayed tachycardia detection to minimize shock discharges in ICD patients.

Kernaussagen

Vermeidung von ICD-Schockabgaben bei gleichzeitiger Sicherstellung der (rechtzeitigen) Abgabe notweniger Schocks (Tab. [2]):

  • Vermeidung inadäquater Schockabgaben durch Aktivierung der VT/SVT-Diskriminierung und spezieller Algorithmen zur Früherkennung von Elektrodendefekten

  • Verlängerung der Tachykardiedetektion auf 30 konsekutive Intervalle in den Zonen bis 187/min und auf „30 aus 40“ Intervalle bei Zonen ≥ 188 /min

  • viele ventrikuläre Tachyarrhythmien terminieren in diesem Zeitraum spontan

  • Limitierung der ICD-Therapien auf Tachykardien > 187/min bei Patienten mit primärprophylaktischer Indikation möglich

  • Cave: Bei Patienten mit sekundärprophylaktischer Indikation, vor allem bekannten monomorphen Tachykardien, unter Amiodaron-Therapie, nach Ablation von Kammertachykardien oder sehr niedriger linksventrikulärer Ejektionsfraktion Risiko für Tachykardien unterhalb der Detektionsfrequenz

  • antitachykarde Stimulation (z. B. 2 Bursts à 8 Zyklen bei 85 – 88 % der Tachykardie-Zykluslänge) bis zu Frequenzen von 250 /min aktivieren, weil damit bei ca. 80 % der Patienten ICD-Schockabgaben vermieden werden können

  • antitachykarde Stimulation während Aufladung des ICD zur Schockabgabe bei vielen Systemen aktivierbar

  • ICD-Schocks auf maximale Energie programmieren, um während der Ladezeit Spontanterminierung von Tachykardien zu ermöglichen

 

  • Literatur

  • 1 Markewitz A. Jahresbericht 2011 des Deutschen Herzschrittmacher- und Defibrillatorregisters. Herzschr Elektrophys 2013; 24: 249-274
    CrossrefPubMedSearch in Google Scholar
  • 2 Löwel H, Hörmann A, Gostomzyk J et al. Epidemiologie des plötzlichen Herztodes: Was hat sich verändert? Ergebnisse des MONICA Augsburg Herzinfarktregisters 1985–1995. Herzschr Elektrophys 1999; 10: II/1-II/7
    PubMedSearch in Google Scholar
  • 3 Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation 1992; 85: I2-10
    PubMedSearch in Google Scholar
  • 4 Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation 2014; 129: e28-e292
    CrossrefPubMedSearch in Google Scholar
  • 5 Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883
    CrossrefPubMedSearch in Google Scholar
  • 6 Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237
    CrossrefPubMedSearch in Google Scholar
  • 7 Al-Khatib SM, Hellkamp A, Bardy GH et al. Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs. clinical trials. JAMA 2013; 309: 55-62
    CrossrefPubMedSearch in Google Scholar
  • 8 Parkash R, Sapp JL, Basta M et al. Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit. Circ Arrhythm Electrophysiol 2012; 5: 706-713
    CrossrefPubMedSearch in Google Scholar
  • 9 Weber M, Block M, Brunn J et al. Inadäquate Therapien durch implantierte Cardioverter-Defibrillatoren – Inzidenz, Ursachen, prädiktive Faktoren und Vermeidungsstrategien. Z Kardiologie 1996; 85: 809-819
    PubMedSearch in Google Scholar
  • 10 Kleemann T, Hochadel M, Strauss M et al. Comparison between atrial fibrillation-triggered implantable cardioverter-defibrillator (ICD) shocks and inappropriate shocks caused by lead failure: different impact on prognosis in clinical practice. J Cardiovasc Electrophysiol 2012; 23: 735-740
    CrossrefPubMedSearch in Google Scholar
  • 11 Daubert JP, Zareba W, Cannom DS et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008; 51: 1357-1365
    CrossrefPubMedSearch in Google Scholar
  • 12 Arya A, Haghjoo M, Emkanjoo Z et al. Does the rate of inappropriate therapy differ in implantable cardioverter-defibrillators from different manufacturers?. J Interv Card Electrophysiol 2006; 17: 59-63
    PubMedSearch in Google Scholar
  • 13 Veltmann C, Kuschyk J, Schimpf R et al. Prevention of inappropriate ICD shocks in patients with Brugada syndrome. Clin Res Cardiol 2010; 99: 37-44
    CrossrefPubMedSearch in Google Scholar
  • 14 Hreybe H, Ezzeddine R, Barrington W et al. Relation of advanced heart failure symptoms to risk of inappropriate defibrillator shocks. Am J Cardiol 2006; 97: 544-546
    CrossrefPubMedSearch in Google Scholar
  • 15 Bourke JP, Turkington D, Thomas G et al. Florid psychopathology in patients receiving shocks from implanted cardioverter-defibrillators. Heart 1997; 78: 581-583
    CrossrefPubMedSearch in Google Scholar
  • 16 Piotrowicz K, Noyes K, Lyness JM et al. Physical functioning and mental well-being in association with health outcome in patients enrolled in the Multicenter Automatic Defibrillator Implantation Trial II. Eur Heart J 2007; 28: 601-607
    PubMedSearch in Google Scholar
  • 17 Francis J, Johnson B, Niehaus M. Quality of life in patients with implantable cardioverter defibrillators. Indian Pacing Electrophysiol J 2006; 6: 173-181
    PubMedSearch in Google Scholar
  • 18 Poole JE, Johnson GW, Hellkamp AS et al. Prognostic importance of defibrillator shocks in patients with heart failure. Engl J Med 2008; 359: 1009-1017
    CrossrefPubMedSearch in Google Scholar
  • 19 Epstein AE, Kay GN, Plumb VJ et al. Gross and microscopic pathological changes associated with nonthoracotomy implantable defibrillator leads. Circulation 1998; 98: 1517-1524
    CrossrefPubMedSearch in Google Scholar
  • 20 Hurst TM, Hinrichs M, Breidenbach C et al. Detection of myocardial injury during transvenous implantation of automatic cardioverter-defibrillators. J Am Coll Cardiol 1999; 34: 402-408
    CrossrefPubMedSearch in Google Scholar
  • 21 Birnie DH, Parkash R, Exner DV et al. Clinical predictors of Fidelis lead failure: report from the Canadian Heart Rhythm Society Device Committee. Circulation 2012; 125: 1217-1225
    CrossrefPubMedSearch in Google Scholar
  • 22 Almendral J, Arribas F, Wolpert C et al. Dual-chamber defibrillators reduce clinically significant adverse events compared with single-chamber devices: results from the DATAS (Dual chamber and Atrial Tachyarrhythmias Adverse events Study) trial. Europace 2008; 10: 528-535
    CrossrefPubMedSearch in Google Scholar
  • 23 Friedman PA, McClelland RL, Bamlet WR et al. Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study. Circulation 2006; 113: 2871-2879
    CrossrefPubMedSearch in Google Scholar
  • 24 Bänsch D, Steffgen F, Grönefeld G et al. The 1+1 trial: a prospective trial of a dual- versus a single-chamber implantable defibrillator in patients with slow ventricular tachycardias. Circulation 2004; 110: 1022-1029
    CrossrefPubMedSearch in Google Scholar
  • 25 Wilkoff BL, Cook JR, Epstein AE et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002; 288: 3115-3123
    CrossrefPubMedSearch in Google Scholar
  • 26 Dorian P, Philippon F, Thibault B et al. Randomized controlled study of detection enhancements versus rate-only detection to prevent inappropriate therapy in a dual-chamber implantable cardioverter-defibrillator. Heart Rhythm 2004; 1: 540-547
    CrossrefPubMedSearch in Google Scholar
  • 27 Wilkoff BL, Ousdigian KT, Sterns LD et al. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol 2006; 48: 330-339
    CrossrefPubMedSearch in Google Scholar
  • 28 Swerdlow CD, Gunderson BD, Ousdigian KT et al. Downloadable algorithm to reduce inappropriate shocks caused by fractures of implantable cardioverter-defibrillator leads. Circulation 2008; 118: 2122-2129
    CrossrefPubMedSearch in Google Scholar
  • 29 Spencker S, Coban N, Koch L et al. Potential role of home monitoring to reduce inappropriate shocks in implantable cardioverter-defibrillator patients due to lead failure. Europace 2009; 11: 483-488
    PubMedSearch in Google Scholar
  • 30 Wilkoff BL. Programming strategies associated with shock reduction in 88. 804 implantable defibrillator patients. Paper presented at: Late breaking clinical trials. Heart Rhythm Society 31st Annual Scientific Sessions. Denver, CO: 05/2010
    PubMedSearch in Google Scholar
  • 31 Moss AJ, Schuger C, Beck CA et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012; 367: 2275-2283
    CrossrefPubMedSearch in Google Scholar
  • 32 Bänsch D, Castrucci M, Böcker D et al. Ventricular tachycardias above the initially programmed tachycardia detection interval in patients with implantable cardioverter-defibrillators: incidence, prediction and significance. J Am Coll Cardiol 2000; 36: 557-565
    CrossrefPubMedSearch in Google Scholar
  • 33 Wilkoff BL, Williamson BD, Stern RS et al. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol 2008; 52: 541-550
    CrossrefPubMedSearch in Google Scholar
  • 34 Gasparini M, Proclemer A, Klersy C et al. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA 2013; 309: 1903-1911
    CrossrefPubMedSearch in Google Scholar
  • 35 Volosin KJ, Exner DV, Wathen MS et al. Combining shock reduction strategies to enhance ICD therapy: a role for computer modeling. J Cardiovasc Electrophysiol 2011; 22: 280-289
    CrossrefPubMedSearch in Google Scholar
  • 36 Kloppe A, Proclemer A, Arenal A et al. Efficacy of Long Detection Interval ICD Settings in Secondary Prevention Population: Data from the Advance III Trial. Circulation 2014; [Epub ahead of print]
    PubMedSearch in Google Scholar
  • 37 Wathen MS, Sweeney MO, DeGroot PJ et al. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation 2001; 104: 796-801
    CrossrefPubMedSearch in Google Scholar
  • 38 Wathen MS, DeGroot PJ, Sweeney MO et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators. Circulation 2004; 110: 2591-2596
    CrossrefPubMedSearch in Google Scholar
  • 39 Jiménez-Candil J, Arenal A, García-Alberola A et al. Fast ventricular tachycardias in patients with implantable cardioverter-defibrillators: efficacy and safety of antitachycardia pacing. A prospective and randomized study. J Am Coll Cardiol 2005; 45: 460-461
    CrossrefPubMedSearch in Google Scholar